Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: The CLASS study

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 1, 2011, Pages 151-159

  Rossolini, Gian M ^a,b   Dryden, Matthew S ^c   Kozlov, Roman S ^d   Quintana, Alvaro ^e   Flamm, Robert K ^e   Läuffer, Jörg M ^f   Lee, Emma ^g   Morrissey, Ian ^h  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^d SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f Janssen Cilag   (Switzerland)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

^h Quotient Bioresearch Ltd   (United Kingdom)

Author keywords

Broad spectrum; Cephalosporins; Etest; MRSA; Surveillance

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; LINEZOLID; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; EUROPE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE EAST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE EAST;

EID: 78650411568     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq397     Document Type: Article

References (30)

1. Hebeisen P, Heinze-Krauss I, Angehrn P et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001; 45: 825-36.
2. Deshpande L, Rhomberg PR, Fritsche TR et al. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary gram-positive and gram-negative isolates. Diagn Microbiol Infect Dis 2004; 50:73-5.
3. Deshpande LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect 2003; 9:1120-4.
4. Goldstein EJ, Citron DM, Merriam CV et al. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006; 50: 3959-62.
5. Pillar CM, Aranza MK, Shah D et al. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J Antimicrob Chemother 2008; 61: 595-602.
6. Zhanel GG, Voth D, Nichol K et al. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 2009; 64:364-9.
7. Amsler KM, Davies TA, Shang W et al. In vitro activity of ceftobiprole against pathogens from two phase 3 complicated skin and skin structure infection clinical trials. Antimicrob Agents Chemother 2008; 52: 3418-23.
8. Walkty A, Decorby M, Nichol K et al. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study. J Antimicrob Chemother 2008; 62: 206-8.
9. Noel GJ, Strauss R, Shah A et al. Ceftobiprole (BPR) versus ceftazidime (CAZ) combined with linezolid (LZD) for treatment of patients with nosocomial pneumonia (NP). In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Forty-sixth Annual Meeting, Washington, DC, 2008. Abstract K-486, p. 444. American Society for Microbiology, Washington, DC, USA.
10. AB bioMérieux. iEtest For MIC Determination (INTL). http://www.abbiodisk.com/bd_litt_prodPackIns.html (27 November 2007, date last accessed).
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
12. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Eighth Edition: Approved Standard M7-A8. CLSI, Wayne, PA, USA, 2009.
13. Kollef MH. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc 2009; 11: 282-6.
14. Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009; 59 Suppl 1: S4-16.
15. Stevens DL. Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. J Infect 2009; 59 Suppl 1: S32-9.
16. Deresinski SC. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials. Diagn Microbiol Infect Dis 2008; 61: 103-9.
17. Zhanel GG, Lam A, Schweize F et al. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008; 9: 245-54.
18. Noel GJ, Bush K, Bagchi P et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: 647-55.
19. Noel GJ, Strauss RS, Amsler K et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008; 52: 37-44.
20. Stein RA, Goetz RM, Ganea GM. Ceftobiprole: a new b-lactam antibiotic. Int J Clin Pract 2009; 63: 930-43.
21. Biedenbach DJ, Bell JM, Sader HS et al. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother 2009; 53: 1260-3.
22. Loza E, Morosini MI, Pascual A et al. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)]. Enferm Infecc Microbiol Clin 2008; 26: 489-94.
23. Reinert RR, Low DE, Rossi F et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60: 1018-29.
24. Sader HS, Watters AA, Fritsche TR et al. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis 2007; 7: 29.
25. Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 3162-5.
26. Swenson JM, Anderson KF, Lonsway DR et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol 2009; 47: 2013-7.
27. Morales G, Picazo JJ, Baos E et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50: 821-5.
28. Jones RN, Ross JE, Bell JM et al. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn Microbiol Infect Dis 2009; 65: 404-13.
29. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 1.1 April 2010. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.1.pdf (11 July 2010, date last accessed).
30. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis 2008; 61: 86-95.